Aurinia Pharmaceuticals

Sustainability Report and Carbon Intensity Rankings

Is Aurinia Pharmaceuticals doing their part?

Their DitchCarbon score is 48

Aurinia Pharmaceuticals has a DitchCarbon Score of 48 out of 100, indicating a moderate level of sustainability in their operations. This score suggests that the company’s carbon intensity is relatively high, implying there is significant room for improvement in reducing emissions. A higher score would reflect a stronger commitment to lowering carbon intensity and enhancing sustainability efforts.

This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.

Industry emissions intensity

Very low




Very high

Aurinia Pharmaceuticals is part of the industrial manufacturing sector, which has a very low carbon intensity ranking compared to other industries. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.

Location emissions intensity

Very low




Very high

Aurinia Pharmaceuticals is situated in Canada, a region with a very low carbon intensity rating. This favorable environmental context supports the company’s sustainability efforts by associating it with a low carbon footprint due to the country’s clean energy practices and policies.

...this company is doing 6.71% better in emissions than the industry average.

Aurinia Pharmaceuticals, founded in 2013, is situated in Victoria, British Columbia, and operates within the industrial manufacturing sector. As a clinical stage biopharmaceutical company, it dedicates itself to the development and commercialization of novel treatments for patients with serious diseases lacking adequate therapies. Aurinia’s global reach underscores its commitment to addressing significant unmet medical needs across various populations.

Bad news, Aurinia Pharmaceuticals hasn't committed to SBTi goals yet

Aurinia Pharmaceuticals has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company has not publicly defined or committed to precise, science-based emissions reduction targets aligned with climate science.

There’s always room for improvement,

DitchCarbon recommends...

Aurinia Pharmaceuticals should consider implementing more rigorous monitoring and reporting practices for their Scope 1 emissions to uncover potential areas for emission reductions.
Not participating

Get unlimited free access to SBTI data via API

Reduce emissions with actionable insights on all your suppliers, embedded seamlessly into your procurement stack

Case study — How Compleat's clients use our carbon data

Making Compleat’s customers climate heroes. Download the 19-page case study PDF.

Claim this profile

Are you associate with this company?
Help us improve our data and claim this profile.

Our methodology

Read about our emission calculation methodologies, and what the DitchCarbon Score means.